Thymidylate Synthase Expression Determines Pemetrexed Targets and Resistance Development in Tumour Cells
Authors:
Open Access
- 13 May 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (5) , e63338
Abstract
Although treatment options for cancer patients are increasing every year, the drug resistance problem remains very present. It is very difficult to find a drug that acts equally on tumours of the same histology as the individual's genetic characteristics often determine the response to treatment. Furthermore, tumours that initially respond to anti-tumour therapy are able to adapt and develop resistance to the drug, while others do not. In addition, this usually implies resistance development to agents to which the cells have not been exposed, a phenomenon called cross-resistance or multidrug resistance. Given this situation, it has been suggested that the most appropriate treatment would be able to act in parallel on multiple pathways constitutively altered in tumour cells. Pemetrexed is a multitargeted antifolate that exerts its activity against folate-dependent enzymes involved in de novo pyrimidine and purine synthesis. It is currently in use in combination with cisplatin against malignant pleural mesothelioma and non-squamous non-small cell lung cancer with favourable results. By real-time RT-PCR gene expression assays and restoration viability assays we demonstrated that Pemetrexed targets folate-dependent enzymes involved in de novo biosynthesis of purines differently depending on the intrinsic genetic characteristics of the tumour. These differences did not, however, interfere either with the initial response to the drug or with the activation of apoptotic pathways. In addition, these genetic fingerprints can differentiate two groups of tumours: those capable of developing resistance to antifolate, and not capable. These results may be useful to employ targets gene expression as resistance markers, a valuable tool for identifying patients likely to receive combination therapy to prevent the development of resistance.Keywords
This publication has 24 references indexed in Scilit:
- Molecular mechanism implicated in Pemetrexed-induced apoptosis in human melanoma cellsMolecular Cancer, 2012
- Expression and Function of Bcl-2 Proteins in MelanomaCurrent Genomics, 2008
- mTORC1 promotes survival through translational control of Mcl-1Proceedings of the National Academy of Sciences, 2008
- In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expressionInvestigational New Drugs, 2007
- Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatmentBritish Journal of Dermatology, 2007
- Akt-dependent transformation: there is more to growth than just survivingOncogene, 2005
- 5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside Inhibits Cancer Cell Proliferation in Vitro and in Vivo via AMP-activated Protein KinaseJournal of Biological Chemistry, 2005
- Pharmacology and Mechanism of Action of PemetrexedClinical Lung Cancer, 2004
- TSC2 Mediates Cellular Energy Response to Control Cell Growth and SurvivalCell, 2003
- Cancer multidrug resistance.2000